மரபணு அட்லஸ் ஆராய்ச்சி வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மரபணு அட்லஸ் ஆராய்ச்சி வலைப்பின்னல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மரபணு அட்லஸ் ஆராய்ச்சி வலைப்பின்னல் Today - Breaking & Trending Today

Frontiers | No Association Between Statin Use and the Prognosis of Endometrial Cancer in Women With Type 2 Diabetes

4
1PEDEGO Research Unit, Medical Research Center Oulu, Department of Obstetrics and Gynecology, Oulu University Hospital and University of Oulu, Oulu, Finland
2Cancer and Translational Medicine Research Unit, Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland
3Department of Obstetrics and Gynecology, Central Finland Central Hospital, Jyväskylä, Finland
4Department of Oncology, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland
Preclinical studies have suggested statins have antiproliferative and anti-metastatic effects on endometrial cancer cells. Similarly, most previous epidemiological studies have reported a better prognosis of endometrial cancer in patients who used statins. In this study, we explored the role of statins in the prognosis of endometrial cancer in women with type 2 diabetes in a hospital-based cohort. This retrospective cohort consisted of 119 women with type 2 ....

United States , Ch Ungch Ong Namdo , South Korea , Paijanne Tavastia , San Diego , Satakunta Region , Mellersta Osterbotten , Ha Afon , Kjaer Hansen , Van Arsdale , Mc Menamin , Andrew Tompkins , Bokhman Redux , National Supervisory Authority Of Welfare , Oulu University Hospital , Israeli Gynecologic Oncology Group Study Of Statin , University Hospital Of Oulu , Finnish Medical Society Duodecim , Cancer Genome Atlas Research Network , Finnish Government Research Funds , Graphpad Software , Finnish Society Of Internal Medicine , International Federation Of Gynecology , Advisory Board Of The Finnish Diabetes Society , Aatos Erkko Foundation , Ethics Committee Of Oulu University Hospital ,

Exelixis : Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU

– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy –

– Data to be presented during the 2021. | February 16, 2021 ....

United States , Sumanta Pal , John Wright , Gisela Schwab , National Cancer Institute , Cancer Therapy Evaluation Program , Takeda Pharmaceutical Company , Product Development , Exelixis Inc , Kidney Cancer Program , Cancer Research Network , Cancer Genome Atlas Research Network , European Union , American Cancer Society , Development Agreement , National Clinical Trials Network , Investigational Drug Branch , National Institutes Of Health , Exchange Commission , Research Network , Oral Abstract Session , Renal Cell Cancer , Clinical Oncology , Genitourinary Cancers Symposium , Clinical Professor , Associate Branch Chief ,

Exelixis Highlights Positive Results for CABOMETYX (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU

® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,
1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13
th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. The findings will be simultaneously published in
The Lancet.
“This is the first randomized trial specific to metastatic papillary renal cell carcinoma to show a clinically and statistically significant benefit with a targeted therapy, CABOMETYX, over an existing standard of care,” said Dr. Sumanta Pal, Clinical Professor and Co-Director of the Kidney Cancer Pro ....

United States , Susan Hubbard , Sumanta Pal , Lindsay Treadway , John Wright , Gisela Schwab , National Cancer Institute , Cancer Therapy Evaluation Program , Takeda Pharmaceutical Company , Product Development , Exelixis Inc , Kidney Cancer Program , Public Affairs , Cancer Research Network , Cancer Genome Atlas Research Network , European Union , American Cancer Society , Development Agreement , National Clinical Trials Network , Investigational Drug Branch , National Institutes Of Health , Exchange Commission , Research Network , Oral Abstract Session , Renal Cell Cancer , Clinical Oncology ,